Brain hypothermic therapy dramatically decreases elevated blood concentrations of high mobility group box 1 in neonates with hypoxic-ischemic encephalopathy

Dis Markers. 2013;35(5):327-30. doi: 10.1155/2013/327604. Epub 2013 Sep 22.

Abstract

Background: According to the Consensus 2010 of the International Liaison Committee on Resuscitation (ILCOR), children with moderate to severe hypoxic-ischemic encephalopathy (HIE) should receive brain hypothermic therapy (BHT) after successful resuscitation. Elevated high mobility group box 1 (HMGB1) in the blood at the early stage of brain ischemia-reperfusion injury has been suggested to be involved in the release of various inflammatory cytokines.

Methods: In total, 21 neonates plasma HMGB1 concentration was measured. These neonates included 8 with HIE in whom BHT was indicated, 5 controls diagnosed as having HIE but who were not suitable candidates for BHT, and 8 normal controls.

Results: The umbilical artery HMGB1 (UA-HMGB1) level before undergoing BHT significantly exceeded reference values. The UA-HMGB1 level in the BHT (-) group did not differ significantly from reference values, but was significantly increased 24 hours after birth. Repeated measure ANOVA showed a significant difference in time course changes between the BHT (+) and BHT (-) groups (P = 0.0002).

Conclusions: This study demonstrated hypothermic therapy to significantly decrease HMGB1. Furthermore, HMGB1 is a useful index of the inhibition of early stage inflammation.

MeSH terms

  • Case-Control Studies
  • HMGB1 Protein / blood*
  • Humans
  • Hypothermia, Induced / standards*
  • Hypoxia-Ischemia, Brain / blood*
  • Hypoxia-Ischemia, Brain / therapy
  • Infant, Newborn / blood*
  • Infant, Premature / blood*

Substances

  • HMGB1 Protein
  • HMGB1 protein, human